Eckert & Ziegler Strahlen- und Medizinte operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eckert & Ziegler Strahlen- und Medizinte with three other
pharmaceutical manufacturers in Europe:
Dottikon ES Holding AG
sales of 151.75 million Swiss Francs [US$152.66 million]
of which 89%
was Pharma Products),
(801.44 million Turkish Liras [US$149.85 million]
of which 93%
was Human Pharma), and
based in Latvia
(132.41 million Euro [US$150.47 million]
of which 95%
was Final Dosage Forms).
Eckert & Ziegler Strahlen- und Medizinte reported sales of 138.63 million Euro (US$157.53 million)
December of 2017.
a very small
increase of 0.5%
versus 2016, when the company's sales were 137.94 million Euro.
Despite this increase, sales are still
below the level achieved in 2015, when Eckert & Ziegler Strahlen- und Medizinte
reported sales of 140.05 million Euro.
Sales of Isotope Products saw an increase
that was more than double the company's growth rate: sales were up
17.4% in 2017, from
73.33 million Euro to 86.11 million Euro.
Eckert & Ziegler Strahlen- und Medizinte also saw significant increases in sales in
Radiation Therapy (up 4.4% to 25.86 million Euro)
Holding (up 12.5% to 18,000.00 Euro)
Not all segments of Eckert & Ziegler Strahlen- und Medizinte experienced an increase in sales in 2017:
sales of Radiation Pharma fell 33.1% to 26.65 million Euro.